Integra LifeSciences(IART) Prnewswire·2025-05-06 22:45Core Viewpoint - Integra LifeSciences Holdings Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and significant stock price decline [1][2][3]. Financial Performance - For Q1 2025, Integra reported earnings per diluted share of -0.04 per diluted share in the same period last year [2]. - The company provided full-year earnings guidance and a second-quarter revenue outlook that fell significantly short of consensus estimates [2]. - Declines were noted in the Neurosurgery and Tissue Technologies segments, attributed to inventory issues and slower ordering patterns [2]. Stock Market Reaction - Following the announcement of the financial results, Integra's stock price dropped by 13.28 per share on May 5, 2025 [3].